<DOC>
	<DOCNO>NCT00001797</DOCNO>
	<brief_summary>Several study document essential role interleukin-10 ( IL-10 ) prevent prolong exaggerated immune response antigens irritant . Psoriasis , relatively common disease , characterize T cell-mediated inflammation affect skin . In study , safety , tolerance , immunologic effect , clinical activity subcutaneous ( SC ) recombinant human ( rh ) IL-10 evaluated patient moderate-to-severe psoriasis . There 2 group patient , randomize receive either 20 ug/kg rhIL-10 SC 3 time weekly ( 20 patient ) SC placebo ( 10 patient ) . This double-blind phase continue total 12 week principal evaluation comparison baseline 12 week Psoriasis Area Severity Index ( PASI ) score . Patients come initial screening visit day 0 , week 1 , 2 , 4 , 6 , 8 , 12 , follow-up visit week 16 20 . All patient offer rhIL-10 12 week ( follow blind portion study protocol ) . Patients initially receive active medication wish continue rhIL-10 therapy keep drug . This open-label portion study continue additional 12 week . Patients continue active drug evaluate week 14 , 16 , 20 , 24 . Skin disease activity toxicity assess record throughout study . In addition , research study include functional assay assess cytokine secretion immunologic function peripheral blood cell immunohistochemical characterization inflammatory cell skin .</brief_summary>
	<brief_title>Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 Moderate-to-Severe Psoriasis</brief_title>
	<detailed_description>Several study document essential role interleukin-10 ( IL-10 ) prevent prolong exaggerated immune response antigens irritant . Psoriasis , relatively common disease , characterize T cell-mediated inflammation affect skin . In study , safety , tolerance , immunologic effect , clinical activity subcutaneous ( SC ) recombinant human ( rh ) IL-10 evaluated patient moderate-to-severe psoriasis . There 2 group patient , randomize receive either 20 ( micro ) g/kg rhIL-10 SC 3 time weekly ( 20 patient ) SC placebo ( 10 patient ) . This double-blind phase continue total 12 week principal evaluation comparison baseline 12 week Psoriasis Area Severity Index ( PASI ) score . Patients come initial screening visit day 0 , week 1 , 2 , 4 , 6 , 8 , 12 , follow-up visit week 16 20 . All patient offer rhIL-10 12 week ( follow blind portion study protocol ) . Patients initially receive active medication wish continue rhIL-10 therapy keep drug . This open-label portion study continue additional 12 week . Patients continue active drug evaluate week 14 , 16 , 20 , 24 . Skin disease activity toxicity assess record throughout study . In addition , research study include functional assay assess cytokine secretion immunologic function peripheral blood cell immunohistochemical characterization inflammatory cell skin .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Able provide inform consent aspect study full information provide . Age equal 18 65 year . Moderatetosevere stable plaque psoriasis least 6 month duration define follow criterion : 1 ) Classic psoriatic skin lesion without nail involvement , 2 ) Psoriasis Area Severity Index score great 10 ( ) , 3 ) Total body surface area involve great 10 % . Weight le 242 pound . Must able selfadminister medication ( subcutaneous injection ) arrange administration . No unstable psoriatic disease , include erythrodermic , pustular , palmar/plantar variant . No use topical medication psoriasis ( except bland emollient ) 2 week prior study entry . No use systemic medication psoriasis 1 month prior study entry . No patient ECOG Zubrod Performance Status Scale great 2 . No patient acute chronic infection require antimicrobial therapy serious viral ( e.g. , hepatitis , herpes zoster , HIV ) fungal infection effect IL10 immune system completely elucidate treatment could pose additional risk patient . Patients positive PPD receive antituberculous therapy may exclude , opinion infectious consultant , IL10 treatment contraindicate . No patient receive disease modify antiinflammatory drug ( methotrexate , sulfasalazine , gold , hydroxychloroquine , cyclosporin , azathioprine , cyclophosphamide , chlorambucil , retinoids , vitamin D ) . Such drug discontinue least 4 week prior randomization . No pregnant female , nurse mother , patient childbearing age practice birth control , since risk unborn fetus newborn child unknown . No previous history malignancy current malignancy satisfactorily treat basalsquamous cell carcinoma situ cervical carcinoma . No confound medical illness judgment investigator would pose added risk study participant ( e.g. , hepatic , hematologic [ e.g. , hematocrit le equal 28 % platelet count less 100,000/ml ] , neurologic , renal , pulmonary disease ) . No patient serum creatinine great 1.8 creatinine clearance ( CrCl ) less 50 ml/min . No patient abnormal liver function test ( e.g. , serum glumatic oxalacetic transaminase , serum glutamic pyruvic transaminase alkaline phosphatase level great 2.5x upper limit normal ( UNL ) and/or bilirubin level 1.5x UNL ) . No current alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1999</verification_date>
	<keyword>Cytokines</keyword>
	<keyword>Immunomodulation</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Skin</keyword>
	<keyword>Therapy</keyword>
</DOC>